ALX Oncology Holdings Inc. ALXO
ALX Oncology Holdings Inc. (Nasdaq: ALXO) is an oncology drug developer. Its lead program, evorpacept, is in Phase 2 for HER2-positive metastatic breast cancer (ASPEN-09-Breast).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| evorpacept | HER2+ breast cancer | protein/peptide | Phase 2 |
| ALX2004 | EGFR-expressing solid tumors | antibody | Phase 1 |
Recent results and decisions
- May 7, 2026positive ESMO Breast exploratory analysis (n=24): cORR 33% overall, 60% in ccHER2+ (n=10); 5/5 ccHER2+/CD47-high responded, mDOR 20.2 months, mPFS 22.1 months.
All of the patients (n=5/5) with ccHER2-positive disease and high CD47 expression (defined as total membrane staining of >20%) responded (including one complete response and four partial responses), with a median duration of response (mDOR) of 20.2 months and mPFS of 22.1 months.
Filing - Feb 27, 2026positive Exploratory ASPEN-06 analysis: in retained HER2+/CD47-high patients (n=43) ORR 65.0% vs 26.1% for TRP alone, mPFS 18.4 vs 7.0 months (HR 0.39), mOS 17 vs 9.9 months (HR 0.70).
In patients with retained HER2-positive and CD47-high gastric cancer (n=43), evorpacept + HERCEPTIN® (trastuzumab), CYRAMZA® (ramucirumab) and paclitaxel (TRP) generated a 65.0% objective response rate (ORR) versus 26.1% ORR for TRP alone.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.